drugset / Trial / NCT06164379
Efficacy and Safety of Finerenone vs. Spironolactone in Patients With Primary Aldosteronism
RandomizedParallel-groupDouble-blindTreatment
Summary
To study the efficacy and safety of finerenone vs. spironolactone in patients with primary aldosteronism
Timeline
- Start
- 2023-12-16
- Primary completion
- 2024-12-16
- Completion
- 2024-12-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Finerenone | Small molecule | 10 mg | — |
| Subject | Finerenone | Small molecule | 20 mg | — |
| Subject | Finerenone | Small molecule | 30 mg | — |
| Comparator | Spironolactone | Small molecule | 20 mg | — |
| Comparator | Spironolactone | Small molecule | 40 mg | — |
| Comparator | Spironolactone | Small molecule | 60 mg | — |